Strategy

MBC Pharma's strategy is to use its patented intellectual property, expertise and know how in drug discovery and early clinical stage drug development to create potential drugs and offer early-stage opportunities for investors and big Pharma. Our current focus is to rationally design new chemical entities that add significant improvements to known active drugs. This is coupled with rigorous science to demonstrate the benefits of our drug design approach and yield high-value assets.

MBC Pharma supplements privately raised Company funds with NIH grant awards. Since 2005 MBC has been awarded $5.6MM in SBIR/STTR grants from the NIH and continues to pursue such non-dilutive funding.

MBC Pharma has partnered with Maxwell Biotech Group to form a joint venture dedicated to the development of one of its lead compounds - MBC-11. Strategic partnerships like this one will be pursued for other MBC Pharma pipeline compounds.

  MBC ongoing oncology programs are opened for partnerships with pharmaceutical or biotechnology companies. Interested parties may contact us at license@mbcpharma.com for more information.